Crossing the line: NICE’s value for money thresholdBMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i1336 (Published 09 March 2016) Cite this as: BMJ 2016;352:i1336
- John Appleby, chief economist
- King’s Fund, London, UK
For a publicly funded health service, deciding what services and treatments should be available to patients is not just a matter of getting the best value for every (scarce) pound spent but an ethical duty too. Choosing “what’s in and what’s out” quite literally involves decisions about life and death; the cost of getting a decision wrong can be measured not just in wasted resources but in avoidable deaths and lower quality of life. In this respect, the creation of the National Institute for Health and Clinical Excellence (NICE) 17 years ago was a watershed moment. For the first time there was an organisation required to advise the NHS explicitly on what it should offer to patients, drawing on evidence of the clinical benefits and the cost of obtaining those benefits.
But NICE—and the growing number of sister organisations in other countries—faced a problem from the outset. At what point …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.